Clinical Trials
9 trialsNCT01257594 2023-05-25
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Columbia University
Phase 1 Completed
NCT00509431 2020-07-31
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01103375 2018-08-01
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Wake Forest University Health Sciences
Phase 1 Terminated
NCT00609999 2014-07-16
Ph I Dasatinib + Erlotinib in Recurrent MG
Duke University
Phase 1 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00738335 2012-10-04
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
Phase 1 Withdrawn
NCT00227032 2012-03-06
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00418327 2009-08-07
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT00536861 2008-05-29
Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer
Amsterdam UMC, location VUmc
Phase 1 Completed